# Ivosidenib as Post-HSCT Maintenance for AML

> **NCT06707493** · PHASE2 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 75 (estimated)

## Conditions studied

- IDH1 Mutation
- Acute Myeloid Leukemia (AML)
- Hematopoietic Stem Cell Transplant (HSCT)

## Interventions

- **DRUG:** Ivosidenib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06707493
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-16
- **Primary completion:** 2028-01-01
- **Final completion:** 2030-01-01
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06707493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06707493, "Ivosidenib as Post-HSCT Maintenance for AML". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06707493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*